Abel Hall LLC’s Treace Medical Concepts TMCI Stock Holding History

Abel Hall LLC’s Portfolio TMCI Stock Details TMCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$148K	Sell	37,219 -1,413	-4%	-$3.88K	0.03%	792
2026 Q1	$51.8K	Buy	+38,632	New	+$77K	0.01%	741

Other funds holding TMCI

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

CBU

CIBC Bancorp USA Chicago, Illinois $82.3B AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Abel Hall LLC's TMCI Position: Q2 2026 in Review

Abel Hall LLC reduced its Treace Medical Concepts (TMCI) stake by 3.7% in Q2 2026, selling an estimated $3.88K and leaving 37,219 shares worth $148K. The position accounts for 0.03% of the portfolio, ranked #792.

Abel Hall LLC first reported a position in TMCI in Q1 2026 and has held it in 2 quarters since. 116 funds tracked by Wall St. Rank hold TMCI as of Q2 2026.

Abel Hall LLC held 37,219 shares of Treace Medical Concepts worth $148K as of Q2 2026.
Abel Hall LLC sold 1,413 Treace Medical Concepts shares in Q2 2026, an estimated $3.88K.
Treace Medical Concepts made up 0.03% of Abel Hall LLC's portfolio in Q2 2026, its #792 holding.
Abel Hall LLC first reported a position in Treace Medical Concepts in Q1 2026 and has held it in 2 quarters since.
116 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.